Choice and interpretation of statistical tests used when competing risks are present.
about
Identification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime?Understanding competing risks: a simulation point of viewScripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation.Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis.Risk stratification for venous thromboembolism in patients with testicular germ cell tumors.Competing risks survival analysis applied to data from the Australian Orthopaedic Association National Joint Replacement RegistryA comparison of ad hoc methods to account for non-cancer AIDS and deaths as competing risks when estimating the effect of HAART on incident cancer AIDS among HIV-infected men.Competing risk models to estimate the excess mortality and the first recurrent-event hazardsEvaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot.Modelling competing risks in nephrology research: an example in peritoneal dialysis.Mortality and complications of hip fracture in young adults: a nationwide population-based cohort study.Analysis and design of randomised clinical trials involving competing risks endpointsTesting the treatment effect on competing causes of death in oncology clinical trialsMeasures of survival benefit in cancer drug development and their limitations.Mortality and complications after hip fracture among elderly patients undergoing hemodialysisThe use and interpretation of competing risks regression modelsImproved Method to Stratify Elderly Patients With Cancer at Risk for Competing EventsMeasurement and control of bias in patient reported outcomes using multidimensional item response theory.Kaplan-Meier Survival Analysis Overestimates the Risk of Revision Arthroplasty: A Meta-analysisLarge registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years.Risk for arrest: the role of social bonds in protecting foster youth making the transition to adulthood.Psychiatric Predictors of Long-term Transplant-Related Outcomes in Lung Transplant RecipientsComparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare databaseApplying competing risks regression models: an overview.Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation.An Analysis of Tumor- and Surgery-Related Factors that Contribute to Inadvertent Positive Margins Following Soft Tissue Sarcoma Resection.Goodness-of-fit test for monotone proportional subdistribution hazards assumptions based on weighted residuals.High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey.Inverse probability of treatment-weighted competing risks analysis: an application on long-term risk of urinary adverse events after prostate cancer treatments.Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database.A Nomogram to Predict the Benefit of Radiation Therapy After Breast-Conserving Surgery in Elderly Patients with Stage I & ER-Negative, or Stage II/III Disease.Investigation of the freely available easy-to-use software 'EZR' for medical statistics.Competing event risk stratification may improve the design and efficiency of clinical trials: secondary analysis of SWOG 8794.Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation.Moving beyond disease-focused decision making: understanding competing risks to personalize lung cancer treatment for older adultsOverall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.Risk factors for non-cancer health events in patients with head and neck squamous cell carcinoma.
P2860
Q28080914-B43E7261-3AA3-41CC-A2D9-AAEFAA30639EQ31015561-5EF1BB3D-779D-4929-B284-74B220A01C2DQ31026869-137D6E04-FE65-448F-BEE8-F7DE8D9534BFQ33434251-962AC361-B31F-4EF9-AE6B-23FF6CA6AD91Q33590396-128A4EFF-35E7-4A40-85A8-32C782828FF9Q33709582-596590AE-631A-4F26-B455-33D2148BE9DCQ33721818-2B0AE1FD-628D-4929-A61B-897697CD3F0FQ33911799-97F1A230-6804-4F8D-B2EC-AD478258629EQ34334964-78906026-469E-4DF0-A685-395D166755E5Q34738940-CFC2F886-9834-4B6B-AABF-90948C537A10Q34893907-B7227494-0230-413F-9911-EE5867E2F4B7Q35089188-5CDB4B52-095C-486E-8E55-55B15D21AF3AQ35177617-8B45D838-9A5D-446E-B9B1-A5EB70AEAFC6Q35490675-865BDF6E-9E5D-4928-A91A-A91A0E95CDD8Q35684700-FC9F55B4-64F7-4F3B-9DD8-860DE9106B20Q35894830-1C11DE26-B525-4027-A720-01980CD96A5EQ35925651-85E854D8-34E6-4462-9B1A-188636B517C7Q36031189-51580148-0E81-49D6-BE7B-368B6E43AF96Q36100899-0E1E7417-0FA2-4977-A15D-74E69AF9AD69Q36115686-89386715-FE96-4249-826C-226E0AECA3A7Q36314845-E6342284-4E36-4D0E-A58C-533CDDB1F2C3Q36385117-6E099CEF-AB91-4965-B0C9-A95D4E72D62FQ36777008-DA208C8D-8B7C-492B-8DC9-462EC1772E18Q38046436-850BE4E5-B144-4407-B1FA-22CC705D20D5Q38086718-C0ECDBD5-BA79-4BB7-96D4-E167AC9120FEQ39204213-BF1C3A4A-7CAD-4185-BC5C-CD8AC174A84EQ39240242-14CF8204-9FC4-4B0C-B623-1D1EB1E70E95Q39974010-155E3EC1-A0FD-4971-B85C-5DC88A8B8F11Q40128898-0EB3B5AB-5B3A-4E06-B26F-5D18633F26CDQ41252640-934A5513-A598-4C28-B753-A7FD4A085B19Q41458508-81B5E18F-06E5-4184-83FD-1AF71ABCE1DBQ41513106-90FD7D17-F97F-48BA-9092-782D584DA7B6Q41975833-78271848-3724-4AFE-9814-7D109E3D4384Q42276555-D39495CD-F359-4F88-80DF-065FC555F270Q42322235-879EF1BC-16C8-4B1A-BF50-0B6ABB6C0960Q42505606-31446A44-E1FC-4276-BAEB-341897E5A91DQ42910816-402655AA-94C4-457A-8FEC-E0F0ED2A55C2Q43059183-2DA4434C-1F4B-40D4-B0D5-49BA4148A8D6Q43263268-3B63B6E4-D0C2-4FE0-8A82-DEC7DC998443Q43588955-E7C08F2F-D323-4E97-A1AE-978E61412AD0
P2860
Choice and interpretation of statistical tests used when competing risks are present.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Choice and interpretation of statistical tests used when competing risks are present.
@en
Choice and interpretation of statistical tests used when competing risks are present.
@nl
type
label
Choice and interpretation of statistical tests used when competing risks are present.
@en
Choice and interpretation of statistical tests used when competing risks are present.
@nl
prefLabel
Choice and interpretation of statistical tests used when competing risks are present.
@en
Choice and interpretation of statistical tests used when competing risks are present.
@nl
P2860
P356
P1476
Choice and interpretation of statistical tests used when competing risks are present.
@en
P2093
James J Dignam
Maria N Kocherginsky
P2860
P304
P356
10.1200/JCO.2007.12.9866
P407
P577
2008-08-01T00:00:00Z